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Abstract
Background: Acute primary angle closure (PAC) can be refractory to conventional treatment and intraocular
pressure (IOP) is beyond control. Surgical intervention should be considered at the moment. The aim of the study
was to compare small-incision phacotrabeculectomy (phacotrab, small-incision trabeculectomy combined with
phacoemulsification) with phacoemulsification (phaco) in patients with refractory acute PAC and coexisting cataract.
Methods: Analyzed 49 eyes (49 patients) with acute PAC and cataract received small-incision phacotrab (24 eyes)
or phaco (25 eyes) randomly. All these cases were refractory to conventional treatment involved the use of
preoperative topical IOP-lowering agents, corticosteroids, mannitol, methazolamide and paracentesis to reduce IOP.
The effects on best corrected visual acuity (BCVA), IOP, anterior chamber depth (ACD), glaucoma medications, and
complications were observed for twelve months.
Results: After operation BCVA of 18 patients (75 %) in phacotrab group and 20 patients (80 %) in phaco group
improved compared to preoperative vision. No statistically significant differences in mean BCVA were found between
the two groups. The mean postoperative IOP levels at all follow up time points were lower than the mean
preoperative IOP in each group (P <0.001). There was statistically significant difference in mean IOP between the two
groups only at 12 months postoperatively (P = 0.006). The surgical success rate (without medications, IOP≤ 21 mmHg)
was 83.33 % (20 eyes) and 72 % (18 eyes) in phacotrab group and phaco group respectively at 12 months. No
statistically significant differences in the mean ACD were found between the two groups. There were no serious
intra- or post-operative complications in the two treatment groups.
Conclusions: Besides phaco, small incision phacotrab may be another effective and safe choice in the treatment of
patients with refractory acute PAC and coexisting cataract. Whether phacotrab is more effective in IOP control in the
long term needs to be verified in the further.
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Background
Acute primary angle closure (PAC) is one of the most
common ophthalmic emergencies. Many ocular risk fac-
tors have been shown to lead to acute PAC, including
hyperopia, shallow anterior chamber depth (ACD), thick
crystalline lens and short axial length [1]. Without treat-
ment patients may develop primary angle closure glau-
coma (PACG) and progressive vision loss [2]. Higher
rates are reported in Asian populations compared to
other races [3–6]. Prompt and effective intervention is
required to control intraocular pressure (IOP), relieve
pupil block, reopen the anterior angle, avoid further at-
tacks and prevent damage to the optic nerve. The initial
treatment of acute PAC include medications, paracen-
tesis, laser peripheral iridotomy and etc. [7]. The role for
surgical iridectomy and emergency trabeculectomy in
the modern management of acute PAC is diminishing
[8]. But in practice, some cases in Asian eyes are refrac-
tory to conventional treatment and IOP is beyond con-
trol. Surgical intervention may be required. In the study
we defined “refractory” as conventional management did
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not achieve IOP control or relieve symptoms despite
maximally tolerated medications or other non- surgically
methods.
Primary lens extraction as treatment for acute PAC has
been proved to relieve pupil block and result in good IOP
control [9]. Because primary trabeculectomy early in acute
PAC has a greater failure rate and higher incidence of
complications, including shallow anterior chamber, malig-
nant glaucoma, suprachoroidal hemorrhage, and endoph-
thalmitis [10], trabeculectomy alone or combined lens
extraction is occasionally used as the final step in the man-
agement of acute PAC, when all other modalities of treat-
ment is failed [11]. While, with the development of new
surgical technique and shift in views, it has been shown
that trabeculectomy is safe and effective for PACG with
persistent ocular hypertension [12]. The purpose of the
current study was to compare primary small-incision pha-
cotrabeculectomy (phacotrab) with phacoemulsification
(phaco) on visual acuity (VA), IOP, ACD, glaucoma medi-
cations and complications in patients with refractory acute
PAC and coexisting cataract.
Methods
Patients and inclusion criteria
This was a prospective analysis conducted at Xijing hos-
pital in Xi’an, People’s Republic of China. The ethic and
academic board of Xijing hospital approved the study
and all procedures used conformed to the tenets of the
Declaration of Helsinki. The informed consent docu-
ments were signed by all patients. 49 cases (49 eyes)
with refractory acute PAC and coexisting cataract re-
ceived small-incision phacotrab or phaco randomly as
initial treatment from March 2011 to September 2013.
The clinical diagnostic criteria for cataract were as fol-
lows: presence of nucleus sclerosis, cortical cataract, or
subcapsular cataract which confirmed by slit-lamp
examination and ultrasound biomicroscopy (UBM); vis-
ual acuity of 20/50 or worse. The diagnostic criteria for
acute PAC were as follows: presence of typical symptoms
including ocular pain, blurry or halo vision, nausea or
vomiting; presenting IOP of more than 21 mmHg and
the presence of typical signs including conjunctival in-
jection, corneal epithelial edema, mid-dilated unreactive
pupil, over 180 ° of iridotrabecular contact or peripheral
anterior synechiae (PAS), and shallow anterior chamber.
Patients with glaucomatous optic neuropathy, secondary
ocular hypertention, surgery history, and any other ocu-
lar or system diseases were excluded. The serious opa-
city of refractive media, including corneal edema,
inflammatory reaction in the anterior chamber and cata-
ract could lead to the difficulties in fundus examination.
As long as the refractive media was clear enough for
fundus examination after surgery, we confirmed whether
the patients met recruit criteria.
Sixteen patients (8 in each group) had one acute attack
history and discontinuous IOP-lowing medical therapy
previously. First line treatment such as systemic hyperos-
motic agents (intravenous mannitol, 1 mg/kg), oral car-
bonic anhydrase inhibitors (methazolamide, 100 mg every
eight hours), four kinds of topical IOP-lowering agents
(Pilocarpine, timolol, brinzolamide and brimonidine) and
other techniques like anterior chamber paracentesis were
applied as long as the diagnosis of acute PAC was made.
Laser iridotomy could not be performed because of cor-
neal edema or mid-dilated unreactive pupil. Operation
was done after 4 to 5 days of conventional management.
All patients presented significant cataract and PAS
over 180 ° by indentation gonioscopy or UBM. They
underwent a complete ocular examination before sur-
gery, including best corrected visual acuity (BCVA), IOP,
slit-lamp and fundus examination. IOL master or con-
tact A-scan biomicroscopy was performed to measure
the axial length and to calculate IOL power. The value
of visual acuity was converted into that in the logarithm
of the minimum angle of resolution (LogMAR).
Surgery technique
All procedures were performed by one surgeon (D.H.).
The surgical procedure in brief was as follows: after local
anesthesia and sterile procedure, all patients underwent
an anterior chamber paracentesis, 5 min later a standard
phacoemulsification was performed through a 3-mm clear
corneal incision. After a foldable hydrophobic acrylic IOL
(XLSTABI ZO, Carl Zeiss) implantation and removal of
viscoelastic material, the pupil was contacted by intracam-
eral carbachol. The clear corneal incision was hydrosealed
or sutured with one stitch of 10–0 Nylon, depending on
the final wound condition. For phacotrab group, a fornix-
based conjunctival flap (width: 5 mm) was used for trabe-
culectomy. A partial-thickness (approximately 50 % depth)
triangular scleral flap was prepared, measuring approxi-
mately 3 mm at the limbus. Mitomycin C (0.4 mg/mL)
was placed under the sclera flap for 2 to 3 min before irri-
gation with balanced salt solution. A sclerostomy was cre-
ated using a Kelly Descemet’s punch, followed by a
surgical peripheral iridectomy. The sclera flap was closed
with 1 interrupted 10–0 nylon suture on the top and 2 re-
leasable sutures on the waist. The fornix-based conjunc-
tival flap was closed with continuous suture. Postoperative
medications included tobramycin drops and prednisolone
acetate ophthalmic suspension were administrated six
times a day and reduced within 4 to 6 weeks depending
on the degree of postoperative inflammation.
Surgical outcomes
Postoperative data regarding BCVA and IOP (primary
outcome measures), ACD, glaucoma medications and
complications (secondary outcome measures) were
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obtained on week 1 and month 1, 3, 6, 9 and 12. UBM
was performed at 6 month to evaluate ACD. Surgical
success was defined as IOP ≤ 21 mmHg without glau-
coma medications. Sutures removal and bleb needling to
improve bleb function were not considered failure of the
procedure.
Statistical analysis
Statistical analysis was performed using SPSS software
version 17 (SPSS Inc, Chicago, Illinois, USA). Continu-
ous variables were expressed as mean ± standard devi-
ation (SD), and categorical data were represented by
number (n) and percentage (%). Parametric variables
were analyzed using analysis of variance (ANOVA). Vari-
ables were compared using a paired t test. P value of
<0.01 was considered statistically significant.
Results
Baseline characteristics
Of the 49 patients recruited in the study, 24 underwent
phacotrab and 25 age- and sex-matched subjects under-
went phaco. The patient demographics and ocular char-
acteristics were showed in Table 1.
Visual acuity
The pre- and post-operative BCVA (converted into Log-
MAR) of the two treatment groups were shown in
Table 2. No statistically significant differences in mean
BCVA were found between the two groups. 18 patients
(75 %) in phacotrab group and 20 patients (80 %) in
phaco group had improved VA on Snellen’s chart. In
phacotrab group 4 patients retained the same initial VA,
and 2 patients had light perception (LP) before and after
surgery. In phaco group 3 patients retained the same ini-
tial VA, and 2 patients had LP before and after surgery.
(Fig. 1, LP not shown)
Table 1 Patient demographics and ocular characteristics of the
two treatment groups
Phacotrab group Phaco group P
Value
No. of eyes 24 25
Mean age ±
SD (yrs)






21.54 ± 0.90 (20.5-23) 21.77 ± 1.06 (20.3-23.3) 0.41*
Lens thickness
(mm)
4.64 ± 0.45 (3.83-5.36) 4.68 ± 0.48 (3.90-5.51) 0.78*
SD = standard deviation, *Student t test, †Chi-square test
Table 2 Pre- and Post-operative BCVA of the two treatment
groups
LogMAR BCVA Phacotrab group Phaco group P Value
Mean preoperative ± SD 1.21 ± 0.49 1.23 ± 0.43 0.93*
Mean postoperative ± SD
(6 mos)
0.82 ± 0.44 0.80 ± 0.38 0.91*
Mean postoperative ± SD
(12 mos)
0.82 ± 0.41 0.80 ± 0.39 0.85*
P Value 0.003* <0.001*
SD = standard deviation, *Student t test
Fig. 1 Comparison of patients’ pre- and post-operative best corrected
visual acuity of the two treatment groups at six months. a: phacotrab
group; b: phaco group
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Intraocular pressure and success rate
The mean IOP in phacotrab group and phaco group at
the time of acute PAC attack were 51.38 ± 8.52 mmHg
and 52.60 ± 8.15 mmHg respectively. The mean postoper-
ative IOP levels at all follow up time points were lower
than the mean preoperative IOP in each group (P <0.001)
(Fig. 2). There was statistically significant difference in
mean IOP between the two groups only at 12 months
postoperatively (P = 0.006). The mean postoperative IOP
levels at all follow up time points were shown in Table 3.
Starting from the 6 months, 2 eyes required one kind
of IOP-lowering drop, and 2 eyes required two to con-
trol IOP (≤21 mmHg) in phacotrab group. In this group
the success rate was 83.33 % (20 eyes) (without medica-
tions) and 100 % (with medications). In phaco group 2
eyes required one kind of IOP-lowering drop, and 5 eyes
required two to control IOP. In this group the success
rate was 72 % (18 eyes) (without medications) and 100 %
(with medications) respectively. 0.5 % timolol was used
to control IOP, and then brinzolamide was added when
it was not enough to achieve the target IOP.
Anterior chamber depth and complications
The post-operative mean ACD of the two treatment
groups increased (Table 4). No statistically significant
differences in the mean ACD were found between the
two groups at 6 months. In phacotrab group, bleb need-
ling procedure with 5-fluorouracil (5 mg) was performed
in 2 eyes at 3 months. All 24 eyes had diffuse blebs or el-
evated blebs with microcystic changes in the conjunctiva
between 3 months to 12 months. There were no serious
intra- or post-operative complications in the two treat-
ment groups.
Discussion
The timely management of acute PAC is important for
reducing the risk of irreversible damage to the optic
nerve head and preventing recurrent attacks and chronic
angle closure glaucoma (CACG) progression [13]. The
retinal fiber layer thickness may decrease significantly
within 16 weeks after the attack [14]. Delay in presenta-
tion and the time needed to terminate the attack have
been found to have a detrimental effect on the final out-
come [13]. Conventional options involve the use of med-
ical treatment, paracentesis and laser peripheral
iridotomy. In hospital clinics a few patients may be re-
fractory to these treatments and the attack may remain
unbroken. Operative options should be considered to
lower IOP as soon as possible, but the timing of opera-
tions in an acute setting is controversial.
Recently, cyclodiode laser has been described as a safe
and effective alternative in the management of medically
uncontrolled acute PAC, and the authors demonstrate a
good result in five patients only [15]. Most ophthalmolo-
gists would consider that lensectomy or trabeculectomy
is suboptimal in such situation because of greater risk of
operative complications due to the small dimensions of
the chamber and the tendency for choroidaleffusion.
The complications of lensectomy are: corneal edema,
posterior capsular rupture, bleeding, fibrinous inflamma-
tory reaction, and posterior capsular opacification [16].
The complications of trabeculectomy are: shallow anter-
ior chamber, transient IOP elevation, hyphaema, and
aqueous misdirection [17]. In medically unresponsive
cases of acute PAC, higher risk of surgical failure and
complications make trabeculectomy not a preferred
choice [17]. In recent times, technological advances in
Fig. 2 Mean IOP profiles of phacotrab and phaco groups. W: week;
M: month; Preop: before surgery
Table 3 Pre- and Post-operative IOP of the two treatment
groups
IOP (mmHg) Phacotrab group Phaco group P Value
Mean preoperative ± SD 51.38 ± 8.52 52.60 ± 8.15 0.61*
Mean postoperative ± SD
(1 week)
12.58 ± 3.74 13.60 ± 3.63 0.34*
1 month 12.38 ± 3.02 13.64 ± 3.21 0.16*
3 months 13.08 ± 3.15 14.36 ± 2.61 0.13*
6 months 13.04 ± 3.18 14.40 ± 3.01 0.13*
9 months 12.96 ± 2.88 14.44 ± 2.83 0.08*
12 months 13.71 ± 3.99 16.64 ± 3.08 0.006*
P Value <0.001* <0.001*
SD = standard deviation, *Student t test
Table 4 Pre- and Post-operative ACD of the two treatment
groups















P Value <0.001* <0.001*
SD = standard deviation, *Student t test
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phacoemulsification and small-incision trabeculectomy
(SIT) make this option much more viable.
In cases of acute PAC or acute angle-closure glau-
coma, phacoemulsification alone has been shown to
achieve good IOP control [18–20]. But IOP-spikes may
appear in the early postoperative period and pose a po-
tential threat [21]. Phacotrabeculectomy plus intraocular
lens implantation has been shown superior than trabecu-
lectomy which is also superior than phacoemulsification
in decreasing IOP for primary angle closure-glaucoma
(PACG) [22]. Phacotrabeculectomy is more effective
than phacoemulsification alone in controlling IOP in
medically uncontrolled CACG eyes with coexisting cata-
ract [23]. In eyes with synechial angle closure and
cataract, the preferred option is to perform phacotrabe-
culectomy [24]. With the progress of surgical technique,
able to skillfully handle intraoperative and postoperative
complications, more and more doctors tend to solve the
two problems in combination.
The new procedures and devices aim to lower IOP
with a higher safety profile than filtering surgery (trabe-
culectomy/drainage tubes) are collectively termed “min-
imally invasive glaucoma surgery (MIGS)” [25]. But
these technologies are mainly for open angle glaucoma,
surgery for “closed angle” is still dominated by trabecu-
lectomy for Asian eyes [26]. The aim of SIT is to pursue
least tissue injury, less complications and better filtering
effect. SIT has been introduced in the form of small inci-
sion with 3 mm fornix-based conjunctival flap, 1–2 mm
short scleral tunnel instead of scleral flap, suture or no
suture for incision, reducing operation area and tissue
injury [27, 28]. The surgical technique is generally effica-
cious and relatively safe comparing to the standard tra-
beculectomy. One study including 41 eyes with
medically uncontrolled glaucoma adopted the surgical
technique. The glaucoma type included chronic simple
glaucoma, chronic narrow-angle glaucoma, pseudoexfo-
liation glaucoma and pigmentary glaucoma. Most of
these patients had IOP at or below the target IOP after
mean follow-up of 25 months [29]. Another revised pro-
cedure of SIT avoids cutting Tenon’s capsule [30]. The
use of a small 2.5 mm limbal incision obviates subcon-
junctival fibrosis, and it is safer with higher success rate
than conventional trabeculectomy [31].
One important difference between the above SIT studies
is the glaucoma type, open angle vs. closed angle over 180°
in ours. The patients enrolled in our study suffered with
both refractory acute PAC and coexisting cataract. We
compared small-incision phacotrabeculectomy with pha-
coemulsification in treating the two problems. Based on
the patients’ preoperative status and eye characteristics, we
also revised the procedure in order to achieve the best out-
come, including the width of the peritomy, flap size, suture
method and etc. The BCVA of most patients was improved
in phacotrab group (75 %) and phaco group (80 %). The
surgical success rate was 83.33 % in phacotrab group and
72 % in phaco group respectively. The difference in mean
IOP at 12 months between the two groups appeared mar-
ginal. A longer follow-up would be useful to confirm
whether small-incision phacotrab is more effective in IOP
control.
Merits of small-incision phacotrabeculectomy for re-
fractive acute PAC with cataract include: less postopera-
tive inflammatory reaction as phaco, better IOP control
in the long term, less possibility of IOP lowing medica-
tion and progression to glaucoma. In addition, combined
phacotrabeculectomy may help elderly patients with less
psychological and financial burden. Any operative option
should base on the specific condition of ocular diseases
and the premise of no violation of evidence-based medi-
cine, taking the most advantageous way for patients. In
patients with medically uncontrolled glaucoma and cata-
ract, the options are to perform trabeculectomy first
then phacoemulsification, phacoemulsification first and
then trabeculectomy, or phacotrabeculectomy [32]. The
surgical indications of combined phacotrabeculectomy
should be reserved for any one of the following condi-
tions: refractory to drug or laser treatment with high
IOP, attack history or moderate to severe optic nerve
damage, tendency to malignant glaucoma, requirement
of vision improvement, no chance to have 2 separate
surgeries due to ocular or systemic conditions, and poor
adherence or inconvenience of follow-up, etc. Small-
incision phacotrabeculectomy may offer clinical and
technical advantages over the standard combined opera-
tions where conventional treatment fails.
This study may not have sufficient follow-up duration
and sample size to look at other parameters, such as
additional IOP lowing medication and glaucomatous
progression. Multicenter randomized controlled clinical
trials are required to confirm these observations.
Conclusions
Small-incision phacotrabeculectomy may be useful with
a lower risk of surgical complications as the primary sur-
gical intervention for the treatment of patients with re-
fractory acute PAC and coexisting cataract.
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